Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer

Nuclear Medicine Communications

Volumn 33, Issue 6, 2012, Pages 613-620

  Kim, Keunyoung ^a   Kim, Seong Jang ^a   Kim, In Joo ^a   Seong Kim, Yun ^a   Pak, Kyoungjune ^a   Kim, Heeyoung ^a  

^a Pusan National University School of Medicine   (South Korea)

Author keywords

FDG PET; metabolic tumor volume; non small cell lung cancer; prognosis; surgery

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GLYCOLYSIS; HUMAN; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE FREE SURVIVAL; REVIEW; STATISTICAL SIGNIFICANCE; TUMOR VOLUME; VOLUMETRY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR BURDEN;

EID: 84862808930     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328351d4f5     Document Type: Review

References (27)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29. (Pubitemid 38443417)
2. Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. American College of Chest Physicians. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:234S-242SS.
3. Robinson LA, Ruckdeschel JC, Wagner H Jr, Stevens CW. American College of Chest Physicians. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:243S-265S. (Pubitemid 47502811)
4. Steinert HC. PET and PET-CT of lung cancer. Methods Mol Biol 2011; 727:33-51.
5. Ou SH, Zell JA, Ziogas A, Anton-Culver H. Prognostic factors for survival of stage I nonsmall cell lung cancer patients: a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003. Cancer 2007; 110:1532-1541. (Pubitemid 47463068)
6. Chansky K, Sculier JP, Crowley JJ, Giroux D,Van Meerbeeck J, Goldstraw P. International Staging Committee and Participating Institutions. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009; 4:792-801.
7. Suzuki K, Nagai K,Yoshida J, Nishimura M,Takahashi K,Yokose T, Nishiwaki Y. Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma. A comparison of prognostic factors for each pathologic TNM stage based on multivariate analyses. Cancer 1999; 86:1976-1984.
8. Strand TE, Rostad H, Moller B, Norstein J. Survival after resection for primary lung cancer: a population based study of 3211 resected patients. Thorax 2006; 61:710-715. (Pubitemid 44211780)
9. Lee P, Weerasuriya DK, Lavori PW, Quon A, Hara W, Maxim PG, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys 2007; 69:328-333. (Pubitemid 47380105)
10. Lim E, Baldwin D, Beckles M, Duffy J, Entwisle J, Faivre-Finn C, et al. British Thoracic Society, Society for Cardiothoracic Surgery in Great Britain and Ireland. Guidelines on the radical management of patients with lung cancer. Thorax 2010; 65 (Suppl 3):iii1-27.
11. Silvestri GA, Tanoue LT, Margolis ML, Barker J, Detterbeck F. American College of Chest Physicians. The noninvasive staging of non-small cell lung cancer: the guidelines. Chest 2003; 123:147S-156SS.
12. Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000; 343: 254-261. (Pubitemid 30490393)
13. 18F-FDG PET/CT and pathological analysis in non-small cell lung cancer. Eur J Radiol 2009; 72:104-113.
14. Van Loon J, van Baardwijk A, Boersma L, Ollers M, Lambin P, De Ruysscher D. Therapeutic implications of molecular imaging with PET in the combined modality treatment of lung cancer. Cancer Treat Rev 2011; 37:331-343.
15. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer. Lung Cancer 2011; 73:332-337.
16. Sun Z, Aubry MC, Deschamps C, Marks RS, Okuno SH, Williams BA, et al. Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital-and 712 population-based cases. J Thorac Cardiovasc Surg 2006; 131:1014-1020.
17. 18F-FDG PET scans. J Nucl Med 2007; 48: 1449-1458. (Pubitemid 47397395)
18. 18F] fluoro-D-glucose with positron emission tomography in patients with small cell lung cancer. Ann Nucl Med 2011; 25:406-413.
19. 18F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol 2010; 17:2787-2794.
20. 18F-fluoro-2-deoxy- D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer. J Thorac Oncol 2009; 4:822-828.
21. 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2011; 38:1628-1635.
22. 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer. J Thorac Oncol 2009; 4:1331-1336.
23. Chen JC, Huang TW, Cheng YL, Chang H, Tzao C, Huang WS, Lee SC. Prognostic value of 18-FDG uptake in early stage NSCLC. Thorac Cardiovasc Surg 2009; 57:413-416.
24. Kim YS, Kim SJ, Kim YK, Kim IJ, Kim YD, Lee MK. Prediction of survival and cancer recurrence using F-18 FDG PET/CT in patients with surgically resected early stage (stage I and II) non-small cell lung cancer. Neoplasma 2011; 58:245-250.
25. Al-Sarraf N, Gately K, Lucey J, Aziz R, Doddakula K, Wilson L, et al. Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases. Eur J Cardiothorac Surg 2008; 34:892-897.
26. 18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected non-small cell lung carcinoma. Lung Cancer 2010; 69:187-193.
27. 18F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC). Eur J Nucl Med Mol Imaging 2010; 37: 691-698.